BWH Clinical & Research News

NIH Awards Weiner $1.4M a year for five years- Clinical & Research News - For and about the Physicians and Researchers of Brigham and Women's HospitalNIH Awards Weiner $1.4M a year for five years- Clinical & Research News - For and about the Physicians and Researchers of Brigham and Women's Hospital

Skip to contents

October 1, 2006

print page content

Subscribe to this feed

Browse the archive Current issue

In This Issue:

Bar Codes Reduce Pharmacy-Related Potential Adverse Drug Events by 63 Percent at BWH Peer Support for Physicians Letter from the Chief Medical Officer Letter from the BWPO Chairman APS Provides Substance Abuse Consultations Gawande Named MacArthur Fellow Kaban Named Chief of Oral and Maxillofacial Surgery Glimcher Receives Honors for Women in Medicine Life Raft Group Names Fletcher Scientist of the Year Whittemore Appointed to State Credentialing Panel Jen Receives PCHI Thier Physician Leadership Award Smirnakis Receives HHMI Early Career Award Feany Receives Senior Scholar Award Eappen Appointed Vice Chair of Anesthesiology Ruiz Named White House Fellow NIH Awards Weiner $1.4M a year for five years Zhou Receives ASBMR Award Adhere to Drug Sample Policy 2007 National Patient Safety Goals Outpatient Prolonged Service Codes - Medicare Billing JCAHO Pocket Guides Available for Physicians

NIH Awards Weiner $1.4M a year for five years

The National Institutes of Health renewed its commitment to provide $1.4 million in funding per year for 5 years to a team headed by Howard L. Weiner, MD, director of the Multiple Sclerosis Program, for research into antigen-specific therapy for autoimmune diseases of the central nervous system, including multiple sclerosis. The grant supports a team that includes Weiner, Vijay Kuchroo, David Hafler and Laurie Glimcher. “We’re trying to develop the next generation of therapy for MS and other diseases, including diabetes and rheumatoid arthritis,” Weiner said. The research team is looking to modulate the immune system in a targeted way through work with animal models, new vaccine strategies and human studies. “In the next few years, we’re hoping to do clinical trials on new oral and nasal vaccines for MS,” he said.